Skip to main content
SpringerLink
Log in

Dementia with Lewy Bodies

  • Chapter
  • First Online:
Hybrid PET/MR Neuroimaging

  • 1767 Accesses

Abstract

Dementia with Lewy bodies is a progressive neurodegenerative α-synucleinopathy and the third most common cause of dementia, after Alzheimer’s disease and vascular dementia. Early diagnosis is useful for prognostic and therapeutic considerations, and imaging plays an important role in excluding alternative diagnoses and confirming presence of Lewy body pathology. Specific imaging ligands are also being developed to aid in further elucidation of disease pathophysiology and characterization.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

DLB:

Dementia with Lewy bodies

PDD:

Parkinson disease dementia

PD:

Parkinson disease

AD:

Alzheimer disease

FTD:

Frontotemporal dementia

SNCA:

α-synuclein

PSEN2:

Presenilin 2

APP:

Amyloid precursor protein

SNCB:

Synuclein beta

MAPT:

Microtubule-associated protein

SCARB2:

Scavenger receptor class B member 2

GBA:

Glucocerebrosidase

LRKK2:

Leucine-rich repeat kinase 2

PSEN1:

Presenilin 1

APOE ε4:

Apolipoprotein E, ε4

References

  1. Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, et al. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14:1–18.

    Article  Google Scholar 

  2. Coyle-Gilchrist ITS, Dick KM, Patterson K, Rodríquez PV, Wehmann E, Wilcox A, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology [Internet]. Lippincott Williams and Wilkins; 2016 [cited 2020 Jul 17];86:1736–43. Available from: /pmc/articles/PMC4854589/?report=abstract.

    Google Scholar 

  3. McKeith IG, Boeve BF, DIckson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies [Internet]. Neurology. Lippincott Williams and Wilkins; 2017 [cited 2020 Jun 28]. p. 88–100. Available from: https://pubmed.ncbi.nlm.nih.gov/28592453/

  4. O’Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with lewy bodies. Arch Neurol [Internet]. Arch Neurol; 2004 [cited 2020 Jul 9];61:919–25. Available from: https://pubmed.ncbi.nlm.nih.gov/15210531/.

  5. Kemp PM, Holmes C. Imaging in dementia with Lewy bodies : a review. 2007;

    Google Scholar 

  6. Schumacher J, Peraza LR, Firbank M, Thomas AJ, Kaiser M, Gallagher P, et al. Functional connectivity in dementia with Lewy bodies: A within- and between-network analysis. Hum Brain Mapp [Internet]. John Wiley and Sons Inc.; 2018 [cited 2020 Jun 9];39:1118–29. Available from: https://doi.org/10.1002/hbm.23901.

  7. The LBD Spectrum | Lewy Body Dementia Association [Internet]. [cited 2020 Jul 22]. Available from: https://www.lbda.org/go/lbd-spectrum.

  8. Kosaka K. Lewy bodies in cerebral cortex. Report of three cases. Acta Neuropathol [Internet]. Springer-Verlag; 1978 [cited 2020 Jun 28];42:127–34. Available from: https://pubmed.ncbi.nlm.nih.gov/654884/.

  9. Kosaka K, Oyanagi S, Matsushita M, Hori A, Iwase S. Presenile dementia with Alzheimer-, Pick- and Lewy-body changes. Acta Neuropathol [Internet]. Springer-Verlag; 1976 [cited 2020 Jul 11];36:221–33. Available from: https://pubmed.ncbi.nlm.nih.gov/188300/.

  10. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National institute on aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol [Internet]. NIH Public Access; 2012 [cited 2020 Jun 28];123:1–11. Available from: /pmc/articles/PMC3268003/?report=abstract.

    Google Scholar 

  11. Tiraboschi P, Attems J, Thomas A, Brown A, Jaros E, Lett DJ, et al. Clinicians’ ability to diagnose dementia with Lewy bodies is not affected by β-amyloid load. Neurology [Internet]. Lippincott Williams and Wilkins; 2015 [cited 2020 Jun 28];84:496–9. Available from: /pmc/articles/PMC4336072/?report=abstract.

    Google Scholar 

  12. Thomas AJ, Donaghy P, Roberts G, Colloby SJ, Barnett NA, Petrides G, et al. Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. Psychol Med. 2019;49:396–402.

    Article  Google Scholar 

  13. Vann Jones SA, O’Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies [Internet]. Psychol. Med. Cambridge University Press; 2014 [cited 2020 Jul 11]. p. 673–83. Available from: https://pubmed.ncbi.nlm.nih.gov/23521899/.

  14. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22:1689–707.

    Article  Google Scholar 

  15. Kane JPM, Surendranathan A, Bentley A, Barker SAH, Taylor JP, Thomas AJ, et al. Clinical prevalence of Lewy body dementia. Alzheimer’s Res Ther [Internet]. BioMed Central Ltd.; 2018 [cited 2020 Jun 28];10. Available from: https://pubmed.ncbi.nlm.nih.gov/29448953/.

  16. Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol [Internet]. American Medical Association; 2013 [cited 2020 Jul 11];70:1396–402. Available from: https://pubmed.ncbi.nlm.nih.gov/24042491/.

  17. CS L, CD K, ME F, LS H, KO L, LR W, et al. Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies. J Neuropathol Exp Neurol [Internet]. J Neuropathol Exp Neurol; 2017 [cited 2020 Jul 11];76. Available from: https://pubmed.ncbi.nlm.nih.gov/28499012/.

  18. Thomas AJ, Mahin-Babaei F, Saidi M, Lett D, Taylor JP, Walker L, et al. Improving the identification of dementia with Lewy bodies in the context of an Alzheimer’s-type dementia. Alzheimer’s Res Ther [Internet]. BioMed Central Ltd.; 2018 [cited 2020 Jul 11];10. Available from: https://pubmed.ncbi.nlm.nih.gov/29490691/.

  19. Burton EJ, Karas G, Paling SM, Barber R, Williams ED, Ballard CG, et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage. Elsevier BV. 2002;17:618–30.

    Article  CAS  Google Scholar 

  20. Burton EJ, Barber R, Mukaetova-Ladinska EB, Robson J, Perry RH, Jaros E, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer’s disease from dementia with Lewy bodies and vascular cognitive impairment: A prospective study with pathological verification of diagnosis. Brain. 2009;132:195–203.

    Article  CAS  Google Scholar 

  21. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop [Internet]. Neurology. Lippincott Williams and Wilkins; 1996 [cited 2020 Jun 28]. p. 1113–24. Available from: https://pubmed.ncbi.nlm.nih.gov/8909416/.

  22. Jellinger KA. Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies [Internet]. J. Neural Transm. Springer Vienna; 2018. Available from: https://doi.org/10.1007/s00702-017-1821-9.

  23. Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain [Internet]. Acta Neuropathol. 2008 [cited 2020 Jul 11]. p. 1–16. Available from: https://pubmed.ncbi.nlm.nih.gov/18592254/.

  24. Nervi A, Reitz C, Tang MX, Santana V, Piriz A, Reyes D, et al. Familial aggregation of dementia with Lewy bodies. Arch Neurol [Internet]. Arch Neurol; 2011 [cited 2020 Jul 11];68:90–3. Available from: https://pubmed.ncbi.nlm.nih.gov/21220678/.

  25. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science (80- ) [Internet]. Science; 1997 [cited 2020 Jul 11];276:2045–7. Available from: https://pubmed.ncbi.nlm.nih.gov/9197268/.

  26. Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T, Eicher JD, et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol [Internet]. Lancet Publishing Group; 2018 [cited 2020 Jul 11];17:64–74. Available from: /pmc/articles/PMC5805394/?report=abstract.

    Google Scholar 

  27. Yousaf T, Dervenoulas G, Valkimadi PE, Politis M. Neuroimaging in Lewy body dementia. J. Neurol. Dr. Dietrich Steinkopff Verlag GmbH and Co. KG; 2019. p. 1–26.

    Google Scholar 

  28. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, et al. APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol [Internet]. American Medical Association; 2013 [cited 2020 Jul 11];70:223–8. Available from: https://pubmed.ncbi.nlm.nih.gov/23407718/.

  29. Orme T, Guerreiro R, Bras J. The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions [Internet]. Curr. Neurol. Neurosci. Rep. Current Medicine Group LLC 1; 2018 [cited 2020 Jul 11]. Available from: /pmc/articles/PMC6097049/?report=abstract.

    Google Scholar 

  30. Yousaf T, Dervenoulas G, Valkimadi PE, Politis M. Neuroimaging in Lewy body dementia. J Neurol [Internet]. Springer Berlin Heidelberg; 2019;266:1–26. Available from: https://doi.org/10.1007/s00415-018-8892-x.

  31. Dementia With Lewy Bodies Information Page | National Institute of Neurological Disorders and Stroke [Internet]. [cited 2020 Jul 11]. Available from: https://www.ninds.nih.gov/Disorders/All-Disorders/Dementia-Lewy-Bodies-Information-Page.

  32. Braak H, Del Tredici K, Rüb U, De Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging [Internet]. Neurobiol Aging; 2003 [cited 2020 Jul 11];24:197–211. Available from: https://pubmed.ncbi.nlm.nih.gov/12498954/.

  33. Fujishiro H, Ferman TJ, Boeve BF, Smith GE, Graff-Radford NR, Uitti RJ, et al. Validation of the neuropathologic criteria of the third consortium for dementia with lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol [Internet]. NIH Public Access; 2008 [cited 2020 Jul 11];67:649–56. Available from: /pmc/articles/PMC2745052/?report=abstract.

    Google Scholar 

  34. Walker L, Stefanis L, Attems J. Clinical and neuropathological differences between Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies – current issues and future directions. J Neurochem. 2019;150:467–74.

    Article  CAS  Google Scholar 

  35. Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology [Internet]. Neurology; 2007 [cited 2020 Jun 28];69:356–9. Available from: https://pubmed.ncbi.nlm.nih.gov/17646627/.

  36. Oppedal K, Ferreira D, Cavallin L, Lemstra AW, ten Kate M, Padovani A, et al. A signature pattern of cortical atrophy in dementia with Lewy bodies: a study on 333 patients from the European DLB consortium. Alzheimer’s Dement [Internet]. Elsevier Inc.; 2019 [cited 2020 Jul 22];15:400–9. Available from: https://pubmed.ncbi.nlm.nih.gov/30439333/.

  37. Nedelska Z, Ferman TJ, Boeve BF, Przybelski SA, Lesnick TG, Murray ME, et al. Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging [Internet]. Elsevier Inc.; 2015 [cited 2020 Jul 11];36:452–61. Available from: https://pubmed.ncbi.nlm.nih.gov/25128280/.

  38. Harper L, Fumagalli G, Barkhof F, Brain PS, 2016 undefined. MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. academic.oup.com [Internet]. [cited 2020 Jun 9]; Available from: https://academic.oup.com/brain/article-abstract/139/4/1211/2464252.

  39. Peraza LR, Colloby SJ, Firbank MJ, Greasy GS, McKeith IG, Kaiser M, et al. Resting state in Parkinson’s disease dementia and dementia with Lewy bodies: Commonalities and differences. Int J Geriatr Psychiatry [Internet]. John Wiley and Sons Ltd; 2015 [cited 2020 Jul 10];30:1135–46. Available from: /pmc/articles/PMC4737212/?report=abstract.

    Google Scholar 

  40. Delli Pizzi S, Franciotti R, Bubbico G, Thomas A, Onofrj M, Bonanni L. Atrophy of hippocampal subfields and adjacent extrahippocampal structures in dementia with Lewy bodies and Alzheimer’s disease. Neurobiol Aging [Internet]. Elsevier Inc; 2016;40:103–9. Available from: https://doi.org/10.1016/j.neurobiolaging.2016.01.010.

  41. Sauer J et al. Differences between Alzheimer Disease and Dementia with Lewy Bodies: an fMRI study of task-related brain activity. Brain. 2006;4.

    Google Scholar 

  42. Roquet D, Sourty M, Botzung A, Armspach JP, Blanc F. Brain perfusion in dementia with Lewy bodies and Alzheimer’s disease: an arterial spin labeling MRI study on prodromal and mild dementia stages. Alzheimer’s Res Ther [Internet]. BioMed Central Ltd.; 2016 [cited 2020 Jul 9];8. Available from: /pmc/articles/PMC4940880/?report=abstract.

    Google Scholar 

  43. Shams S, Fällmar D, Schwarz S, Wahlund LO, Van Westen D, Hansson O, et al. MRI of the swallow tail sign: a useful marker in the diagnosis of lewy body dementia? Am J Neuroradiol. 2017;38:1737–41.

    Article  CAS  Google Scholar 

  44. Kamagata K, Nakatsuka T, Sakakibara R, Tsuyusaki Y, Takamura T, Sato K, et al. Diagnostic imaging of dementia with Lewy bodies by susceptibility-weighted imaging of nigrosomes versus striatal dopamine transporter single-photon emission computed tomography: a retrospective observational study. Neuroradiology [Internet]. Springer Verlag; 2017 [cited 2020 Jul 22];59:89–98. Available from: https://pubmed.ncbi.nlm.nih.gov/28035426/.

  45. Stormezand GN, Chaves LT, Vállez García D, Doorduin J, De Jong BM, Leenders KL, et al. Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders. NeuroImage Clin. Elsevier Inc.; 2020;25:102161.

    Google Scholar 

  46. Hu XS, Okamura N, Arai H, Higuchi M, Matsui T, Tashiro M, et al. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology [Internet]. Lippincott Williams and Wilkins; 2000 [cited 2020 Jul 11];55:1575–6. Available from: https://pubmed.ncbi.nlm.nih.gov/11094120/.

  47. [Clinical Utility of (18)F-DOPA-PET in Movement Disorders. A Systematic Review] - PubMed [Internet]. [cited 2020 Jul 11]. Available from: https://pubmed.ncbi.nlm.nih.gov/19558950/.

  48. Jokinen P, Helenius H, Rauhala E, Brück A, Eskola O, Rinne JO. Simple ratio analysis of18F-fluorodopa uptake in striatal subregions separates patients with early parkinson disease from healthy controls. J Nucl Med. 2009;50:893–9.

    Article  Google Scholar 

  49. Khamis K, Giladi N, Levine C, Kesler M, Kuten J, Lerman H, et al. The added value of 18 F-FDOPA PET/CT in the Work-Up of patients with movement disorders. Neurographics. 2019;9:344–8.

    Article  Google Scholar 

  50. Nestor PJ, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z, et al. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur J Nucl Med Mol Imaging [Internet]. Springer Berlin Heidelberg; 2018 [cited 2020 Jul 17];45:1509–25. Available from: https://doi.org/10.1007/s00259-018-4035-y.

  51. Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Eur J Neurol [Internet]. John Wiley & Sons, Ltd; 2007 [cited 2020 Jul 11];14:1357–62. Available from: https://doi.org/10.1111/j.1468-1331.2007.01977.x.

  52. Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, Kuhl DE. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol [Internet]. Ann Neurol; 2001 [cited 2020 Jul 11];50:358–65. Available from: https://pubmed.ncbi.nlm.nih.gov/11558792/.

  53. Higuchi M, Tashiro M, Arai H, Okamura N, Hara S, Higuchi S, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol [Internet]. Academic Press Inc.; 2000 [cited 2020 Jul 11];162:247–56. Available from: https://pubmed.ncbi.nlm.nih.gov/10739631/.

  54. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology [Internet]. Lippincott Williams and Wilkins; 2001 [cited 2020 Jul 11];56:643–9. Available from: https://pubmed.ncbi.nlm.nih.gov/11245717/.

  55. O’Brien JT, Firbank MJ, Davison C, Barnett N, Bamford C, Donaldson C, et al. 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med [Internet]. Society of Nuclear Medicine Inc.; 2014 [cited 2020 Jul 11];55:1959–65. Available from: https://pubmed.ncbi.nlm.nih.gov/25453043/.

  56. Seok ML, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-β-CIT SPECT for diagnosis of dementia with lewy bodies. J Nucl Med [Internet]. J Nucl Med; 2009 [cited 2020 Jul 11];50:1638–45. Available from: https://pubmed.ncbi.nlm.nih.gov/19759102/.

  57. Kantarci K, Lowe VJ, Chen Q, Przybelski SA, Lesnick TG, Schwarz CG, et al. β-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology. 2020;94:e282–91.

    Article  CAS  Google Scholar 

  58. Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging [Internet]. Neurobiol Aging; 2012 [cited 2020 Jul 17];33:2091–105. Available from: https://pubmed.ncbi.nlm.nih.gov/22018896/.

  59. Donaghy P, Thomas AJ, O’Brien JT. Amyloid PET imaging in lewy body disorders. Am J Geriatr Psychiatry. Elsevier. 2015;23:23–37.

    Article  Google Scholar 

  60. Berman SB, Miller-Patterson C. PD and DLB: Brain imaging in Parkinson’s disease and dementia with Lewy bodies. Prog Mol Biol Transl Sci. Elsevier B.V.; 2019. p. 167–85.

    Google Scholar 

  61. Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge [Internet]. Mol. Psychiatry. Nature Publishing Group; 2019 [cited 2020 Jul 15]. p. 1112–34. Available from: https://doi.org/10.1038/s41380-018-0342-8.

  62. Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging: present and future directions [Internet]. Mol. Neurodegener. BioMed Central Ltd.; 2017 [cited 2020 Jul 22]. p. 1–21. Available from: https://link.springer.com/articles/10.1186/s13024-017-0162-3.

  63. Gomperts SN, Locascio JJ, Makaretz SJ, Schultz A, Caso C, Vasdev N, et al. Tau positron emission tomographic imaging in the lewy body diseases. JAMA Neurol. 2016;73:1334–41.

    Article  Google Scholar 

  64. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain. 1999;122:1449–68.

    Article  Google Scholar 

  65. Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Rainer M, et al. Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study. Br J Psychiatry [Internet]. Cambridge University Press; 2015 [cited 2020 Jul 22];206:145–52. Available from: https://pubmed.ncbi.nlm.nih.gov/25431431/.

  66. Ransmayr G. Dementia with Lewy bodies: prevalence, clinical spectrum and natural history. J Neural Transm Suppl [Internet]. Springer Wien; 2000 [cited 2020 Jul 11]. p. 303–14. Available from: https://pubmed.ncbi.nlm.nih.gov/11205149/.

  67. McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol [Internet]. Lancet Neurol; 2007 [cited 2020 Jul 22];6:305–13. Available from: https://pubmed.ncbi.nlm.nih.gov/17362834/.

  68. Walker Z, Costa DC, Walker RWH, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology [Internet]. Lippincott Williams and Wilkins; 2004 [cited 2020 Jul 22];62:1568–72. Available from: https://pubmed.ncbi.nlm.nih.gov/15136683/.

  69. Thomas AJ, Attems J, Colloby SJ, O’Brien JT, Mckeith I, Walker R, et al. Autopsy validation of 123 I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology [Internet]. Lippincott Williams and Wilkins; 2017 [cited 2020 Jul 22];88:276–83. Available from: https://n.neurology.org/content/88/3/276.

  70. van der Zande JJ, Joling M, Happach IG, Vriend C, Scheltens P, Booij J, et al. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer’s disease pathology: an 123I-FP-CIT SPECT study. NeuroImage Clin. Elsevier Inc.; 2020;25:102062.

    Google Scholar 

  71. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov. Disord. 2007. p. 1689–707.

    Google Scholar 

  72. Graff-Radford J, Murray ME, Lowe VJ, Boeve BF, Ferman TJ, Przybelski SA, et al. Dementia with Lewy bodies: Basis of cingulate island sign. Neurology [Internet]. Lippincott Williams and Wilkins; 2014 [cited 2020 Jul 22];83:801–9. Available from: https://n.neurology.org/content/83/9/801.

  73. Seok ML, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-β-CIT SPECT for diagnosis of dementia with lewy bodies. J Nucl Med. Society of Nuclear Medicine; 2009;50:1638–45.

    Google Scholar 

  74. Iizuka T, Iizuka R, Kameyama M. Cingulate island sign temporally changes in dementia with Lewy bodies. Sci Rep [Internet]. Nature Publishing Group; 2017 [cited 2020 Jul 17];7:1–9. Available from: www.nature.com/scientificreports/.

  75. Goto H, Ishii K, Uemura T, Miyamoto N, Yoshikawa T, Shimada K, et al. Differential diagnosis of dementia with lewy bodies and alzheimer disease using combined MR imaging and brain perfusion single-photon emission tomography. Am J Neuroradiol [Internet]. AJNR Am J Neuroradiol; 2010 [cited 2020 Jul 9];31:720–5. Available from: https://pubmed.ncbi.nlm.nih.gov/20075101/.

  76. Yeo JM, Lim X, Khan Z, Pal S. Systematic review of the diagnostic utility of SPECT imaging in dementia [Internet]. Eur. Arch. Psychiatry Clin. Neurosci. Eur Arch Psychiatry Clin Neurosci; 2013 [cited 2020 Jul 16]. p. 539–52. Available from: https://pubmed.ncbi.nlm.nih.gov/23917803/.

  77. Galvin JE. Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score. Alzheimer’s Dement Diagnosis, Assess Dis Monit [Internet]. Elsevier Inc.; 2015 [cited 2020 Jul 17];1:316–24. Available from: https://pubmed.ncbi.nlm.nih.gov/26405688/.

  78. Komatsu J, Samuraki M, Nakajima K, Arai H, Arai H, Arai T, et al. I-mibg myocardial scintigraphy for the diagnosis of dlb: a multicentre 3-year follow-up study. J Neurol Neurosurg Psychiatry [Internet]. BMJ Publishing Group; 2018 [cited 2020 Jul 17];89. Available from: https://pubmed.ncbi.nlm.nih.gov/29853532/.

  79. Vigen CLP, Mack WJ, Keefe RSE, Sano M, Sultzer DL, Stroup TS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry [Internet]. NIH Public Access; 2011 [cited 2020 Jul 11];168:831–9. Available from: /pmc/articles/PMC3310182/?report=abstract.

    Google Scholar 

  80. Armstrong MJ, Weintraub D. The Case for Antipsychotics in Dementia with Lewy Bodies [Internet]. Mov. Disord. Clin. Pract. Wiley-Blackwell; 2017 [cited 2020 Jul 11]. p. 32–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353494/.

  81. Boot BP. Comprehensive treatment of dementia with Lewy bodies [Internet]. Alzheimer’s Res. Ther. BioMed Central Ltd.; 2015 [cited 2020 Jul 17]. Available from: https://pubmed.ncbi.nlm.nih.gov/26029267/.

  82. Uc EY, Doerschug KC, Magnotta V, Dawson JD, Thomsen TR, Kline JN, et al. Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology [Internet]. Lippincott Williams and Wilkins; 2014 [cited 2020 Jul 17];83:413–25. Available from: https://pubmed.ncbi.nlm.nih.gov/24991037/.

Download references

Author information

Authors and Affiliations

  1. NewYork Presbyterian-Weill Cornell, Department of Radiology, New York, NY, USA

    Jenifer Pitman & Gloria C. Chiang

Authors
  1. Jenifer Pitman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gloria C. Chiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gloria C. Chiang .

Editor information

Editors and Affiliations

  1. Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, The Feinstein Institutes for Medical Research, Manhasset, NY, USA

    Ana M. Franceschi

  2. Stony Brook University Hospital, Stony Brook, NY, USA

    Dinko Franceschi

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pitman, J., Chiang, G.C. (2022). Dementia with Lewy Bodies. In: Franceschi, A.M., Franceschi, D. (eds) Hybrid PET/MR Neuroimaging. Springer, Cham. https://doi.org/10.1007/978-3-030-82367-2_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-82367-2_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-82366-5

  • Online ISBN: 978-3-030-82367-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation